New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
16:13 EDTQGENQIAGEN announces three separate agreements to add biomarkers
QIAGEN announced three separate agreements that add multiple biomarkers to QIAGEN's development pipeline of diagnostics for Personalized Healthcare applications. QIAGEN intends to develop new diagnostics to guide treatment decisions, including companion diagnostics paired with medicines, based on these biomarkers. Most of these assays will be designed to run on the QIAsymphony RGQ modular laboratory workflow automation system as well as QIAGEN's next-generation sequencing workflows currently in development. QIAGEN has made a strategic equity investment in Drug Response Dx GmbH with the option to obtain worldwide rights to biomarkers for evaluation of rheumatoid arthritis patients to guide treatment with TNF-alpha inhibitors, which are widely prescribed for treatment of RA. QIAGEN has agreed to license exclusive worldwide rights from Insight Genetics for the RET, ROS1 and DEPDC1 biomarkers for use in non-small cell lung cancer, the most common form of lung cancer. QIAGEN Marseille has licensed exclusive worldwide rights to a biomarker for mutations of the HSP110 gene, which allows for identification of specific types of colorectal cancer, from InsermTransfert, the technology transfer arm of the French National Institute of Health and Medical Research.
News For QGEN From The Last 14 Days
Check below for free stories on QGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 10, 2014
16:02 EDTQGENQIAGEN acquires exclusive worldwide license to biomarker calreticulin
Subscribe for More Information
April 2, 2014
09:01 EDTQGENLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools Analyst Leonard discusses the use of nextgen sequencing in a clinical context, early applications and uptake, the merits, demerits of various nextgen sequencing instruments and where new offerings fit on an Analyst/Industry conference call. Relevant companies ILMN, TMO, PACB, FLDM, MYGN, NSTG, GNMK, CPHD, LMNX and QGEN may be discussed on the Analyst/Industry conference call to be held on April 3 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use